• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BARDA awards SwRI $8.3M to continue developing cyanide poisoning antidote

BARDA awards SwRI $8.3M to continue developing cyanide poisoning antidote

March 26, 2014
CenterWatch Staff

The U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) has awarded Southwest Research Institute (SwRI), an independent, nonprofit, applied R&D organization, an $8.3 million contract extension to continue development of a nasal-delivery, first-line treatment system to combat cyanide poisoning using an intranasal formulation of isoamyl nitrite.

The 28-month contract, a follow-on option to a contract begun in 2011, will include development of additional clinical supplies, regulatory filings and testing in two animal models to show safety and efficacy to support FDA approval.

“This antidote could potentially save many lives in an emergency situation by allowing individuals to quickly administer—even self-administer—a life-saving dosage of the isoamyl nitrite intranasally,” said Joe McDonough, Principal Investigator and director of SwRI’s microencapsulation and nanomaterials department. “This formulation, using a nasal delivery method, is relatively low cost and can be quickly and easily administered in a crisis situation, unlike the current method that must be delivered by a trained medical professional.”

Cyanide exposure can prove lethal if not treated quickly and effectively. Current antidotes require intravenous administration, which does not enable quick treatment of large numbers of victims, such as in a terrorist situation. A nasal formulation could potentially save lives by allowing for rapid treatment of large numbers of patients and administration of metered dosages.

In 2011, BARDA awarded SwRI $4.4 million to develop a drug formulation and delivery system to treat cyanide exposure. During the base period of SwRI’s contract, nasal delivery of isoamyl nitrite was shown to be surprisingly effective at treating and rapidly reversing otherwise lethal cyanide exposure during nonclinical testing, said McDonough.

“This is just one more program in SwRI’s 10-year effort to develop antidotes against toxic industrial chemicals and chemical weapons,” said Michael MacNaughton, vice president of the chemistry and chemical engineering division. “SwRI has a long history of developing new technology to support the government.”

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing